A new antibody to help protect brain cells and promote new brain cell growth for Alzheimer's disease treatment
A Novel Antibody that Promotes Neuronal Integrity and Neurogenesis for Treating Alzheimer's Disease
This study is testing a new type of treatment for Alzheimer's disease that uses special antibodies to help protect and support brain cells, with the hope of reducing harmful substances in the brain, and patients may have the chance to participate in trials to see how well it works.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virtici, LLC NIH-funded |
| Lab location | 1 site (Seattle, UNITED STATES) |
| Project ID | NIH-10706541 on NIH RePORTER |
What this research studies
This research focuses on developing a novel bispecific antibody designed to penetrate neurons and promote their integrity and growth, specifically targeting Alzheimer's disease (AD). The approach involves creating antibodies that can enhance the activity of α-secretase while inhibiting β-secretase, which are crucial in the processing of amyloid precursor protein (APP) linked to AD. By reducing harmful amyloid-beta accumulation in the brain, this treatment aims to address a significant unmet need for effective therapies in AD. Patients may be involved in trials to assess the safety and efficacy of this innovative treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those showing early signs of cognitive decline associated with the condition.
Not a fit: Patients with other forms of dementia or cognitive impairments unrelated to Alzheimer's disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that not only alleviates symptoms of Alzheimer's disease but also promotes the regeneration of brain cells.
How similar studies have performed: While there have been various approaches to treating Alzheimer's disease, this specific bispecific antibody strategy is novel and has not been extensively tested in clinical settings.
Where this research is happening
Seattle, UNITED STATES
- Virtici, LLC — Seattle, United States (Active)
Researchers
- Principal investigator: Fanger, Neil a — Virtici, LLC
- Study coordinator: Fanger, Neil a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.